article · Drug Design Development and Therapy
New chemical compounds designed to inhibit histone deacetylase enzymes HDAC1 and HDAC2 have undergone biological evaluation. Among the evaluated analogues, compound 7a demonstrated the strongest inhibitory potency against HDAC1 and HDAC2, recording half-maximal inhibitory concentration values of 114.3 nanomolar and 53.7 nanomolar, respectively. In cell testing, compound 7a proved to be the most effective candidate against SH-SY5Y cells with an inhibitory concentration of 1.60 micromolar, representing a 4.7-fold higher efficiency than the reference drug Gefitinib. In parallel tests on HT-29 cells, another analogue, compound 8a, showed the highest activity with an inhibitory concentration of 1.96 micromolar, outperforming Gefitinib by 2.5 times. These experimental findings indicate that compound 7a represents a promising lead compound suitable for further chemical optimisation and therapeutic development as a targeted histone deacetylase inhibitor.
Histone deacetylase enzymes play key roles in cellular regulation, making them important targets for therapeutic discovery. Identifying small molecules that inhibit these enzymes more potently than existing reference compounds provides valuable starting points for drug design. Demonstrating superior activity against specific disease cell models highlights candidate molecules that could eventually inform the development of more effective targeted therapies.
The research presents early-stage laboratory findings that could be relevant to pharmaceutical companies and biotechnology developers working on histone deacetylase inhibitors. The findings identify compound 7a as a prospective lead candidate for further exploration. Because the results are based solely on in vitro enzymatic assays and preliminary cell line evaluations, the candidate is far from real-world clinical application and requires substantial optimisation, preclinical validation, and safety profiling.
AI-generated from the published abstract. Always read the original work before citing.
Compound <b>7a</b> was found to be the most potent analog in this study toward HDAC1 and HDAC2 with IC<sub>50</sub> values equal 114.3 and 53.7 nM, respectively. Moreover, it was the most effective counterpart (IC<sub>50</sub> = 1.60 µM), with 4.7-fold enhanced efficiency than reference drug Gefitinib (IC<sub>50</sub> = 7.63 µM) against SH-SY5Y cells. Whereas, compound <b>8a</b> (IC<sub>50</sub> = 1.96 µM) was the most active member toward HT-29 cells, being 2.5-times more potent than Gefitinib (IC<sub>50</sub> = 4.99 µM). Collectively, these results suggest that <b>7a</b> merits further optimization and development as an effective new HDACI lead compound.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/dddt.s237957
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
